Oncotarget cover image

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

Mar 25, 2024
Researchers discuss the synergistic effects of ABT199/venetoclax and thiotepa in AML cells, showcasing enhanced apoptosis activation and DNA damage response. The combination shows promise in overcoming drug resistance and reducing pro-survival proteins in leukemia treatment.
03:21

Podcast summary created with Snipd AI

Quick takeaways

  • Combining ABT199/Venetoclax with Thiotepa enhances apoptosis and DNA damage response in AML cells.
  • Researchers suggest potential clinical relevance of the drug combination in overcoming drug resistance mechanisms in AML treatment.

Deep dives

Enhanced Cytotoxicity in AML Cells with Drug Combination

The research paper published in Onco Targets Vol. 15 highlights the synergistic cytotoxicity of ABT199 Venetoclax with Thyotepa Theo in AML cells. Researchers from the University of Texas MD Anderson Cancer Center and the University of Alberta demonstrate that this drug combination enhances apoptosis and DNA damage response, showing potential to overcome drug resistance. The study suggests that combining ABT199 Venetoclax and Thio with other chemotherapeutic drugs like Fludarabene, Cladabene, and Balsulfan could decrease BCL2, BCLXL, and MCL1 levels, indicating clinical relevance in AML treatment.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner